Thus, these results demonstrate that KITD816V-induced autophagy is necessary to drive leukemic progression in vivo, and that autophagy inhibition could represent a valuable therapeutic target in AML with KIT mutations. The gene discussed is KIT; the disease is acute myeloid leukemia.